Anzeige
Mehr »
Login
Sonntag, 20.04.2025 Börsentäglich über 12.000 News von 690 internationalen Medien
Gold auf 4.000 USD? Goldman Sachs sagen Ja - und bei Forge sitzt der Ex-CFO von Newmont mit am Tisch
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QMUH | ISIN: US92790C1045 | Ticker-Symbol: 1S1
Tradegate
17.04.25
14:22 Uhr
11,215 Euro
-0,325
-2,82 %
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
VIRIDIAN THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
VIRIDIAN THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
11,20011,90017.04.
11,20011,90017.04.

Aktuelle News zur VIRIDIAN THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
07.04.Viridian Therapeutics appoints Jeff Ajer to board1
07.04.Viridian Therapeutics, Inc.\DE - 8-K, Current Report1
04.04.Stifel maintains Buy on Viridian Therapeutics, $41 target2
11.03.Viridian Therapeutics Announces Inducement Stock Option Grants1
10.03.Viridian Therapeutics, Inc.\DE - 8-K, Current Report1
VIRIDIAN THERAPEUTICS Aktie jetzt für 0€ handeln
03.03.Viridian Therapeutics, Inc.\DE - S-8, Securities to be offered to employees in employee benefit plans-
03.03.Viridian Therapeutics, Inc.\DE - 10-K, Annual Report-
27.02.Viridian Therapeutics GAAP EPS of -$0.81 beats by $0.24, revenue of $0.07M beats by $0.02M2
27.02.Viridian Therapeutics, Inc.\DE - 8-K, Current Report-
10.01.Viridian Therapeutics, Inc.\DE - 8-K, Current Report-
07.01.Expert Outlook: Viridian Therapeutics Through The Eyes Of 10 Analysts1
17.12.24Breaking Down Viridian Therapeutics: 10 Analysts Share Their Views1
16.12.24Viridian Therapeutics Skyrockets After Besting Amgen In Thyroid Eye Disease39
16.12.24Viridian Therapeutics, Inc.\DE - 8-K, Current Report-
12.11.24Viridian Therapeutics Reports Third Quarter 2024 Financial Results and Recent Progress Including New FcRn Data215WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare...
► Artikel lesen
28.10.24Needham maintains buy on VRDN shares, cites recent clinical trial results4
28.10.24Analyst Expectations For Viridian Therapeutics' Future5
23.10.24Viridian Therapeutics (VRDN): A Small-Cap Biotech with Promising Clinical Results4
08.08.24Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2024 Financial Results165WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare...
► Artikel lesen
08.05.24Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2024 Financial Results176WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare...
► Artikel lesen
20 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1